Blog hero background graphic

Blog

Fast 5: Why did Merck just temper expectations for its oral PCSK9 launch?

Merck's oral PCSK9 pill Lipfendra promises broader access and lower cost than injectable rivals, but a slower launch curve and missing...

Fast 5: Why did Merck just temper expectations for its oral PCSK9 launch?featured image

Four strategies for winning, not just reaching, the biotech launch stage

The Space Life Sciences Podcast

Oncology confidential: candid perspectives from a 28-year oncology sales veteran

The Beghou Biopharma Review

The conference season, distilled, in this summer debrief

Threat from within: Why biopharma's drug development bottleneck is systemic

The physician feedback loop: What HCPs are telling pharma and healthcare market research

The Beghou Biopharma Review

H1’s most consequential commercialization trends; 3 questions for Star Therapeutics’ Jacob Lai

Why Medical Affairs must be integrated into field strategy

Making AI work for your first launch: Where it drives commercial and medical impact, and where it doesn't

Biopharma’s own AI myth-busters separate tall tale from truism

4 ways leading pharma teams are rethinking IC

Fast 5: MFN has reset pharma launch strategy

Commercializing at FDA Speed in Emerging Biopharma

The Space Life Sciences Podcast

Why capital efficiency anchors biotech’s new commercial playbook

When your data hits a wall: A pragmatic framework for life sciences leaders before investing in more data

Pharma search tipping point: Moving from the solo act of SEO to GEO